All In Biotech

Drug Trial Radar · NCT07684157

A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

A Phase IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JAB-8263 in Patients With Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 23, 2026

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • JAB-8263Drug

    Variable dose1, orally Q2D with 28 days

  • JAB-8263Drug

    Variable dose2, orally Q2D with 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the overall safety and tolerability of JAB-8263Time frame: Up to approximately 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.